Novavax vaccine effective against the Omicron variant. While the administration of the first protein authorized in the EU has begun in Europe “, the preliminary data – underlined Marco Cavaleri, head of Vaccines and Covid-19 Therapeutic Products of the EMA, during the periodic update for the press – are showing that the induced immune response from Nuvaxovid after primary vaccination achieves neutralization of Omicron, albeit with “lower efficacy than other Sars-CoV-2 variants, similar to that observed with mRna vaccines”.
In addition, Ema will evaluate Novavax for the use of a third dose and the extension of use even under 18 years of age, in adolescents between 12 and 17 years of age. “To support” possibly these indications, “we will discuss the latest clinical trial results with the American company.”
#Novavax #vaccine #Omicron #variant #Ema #Effective #primary #cycle